

ESMO 2024 Industry Satellite Symposium

# Precision oncology for *BRAF*-mutant cancers

Monday, 16 September 2024, 18:30–20:00 (CEST)

Salamanca Auditorium, Hall 5  
Fira Barcelona Gran Via, Barcelona, Spain

Join the world-renowned expert faculty  
share their **clinical experience of treating  
patients with *BRAF*<sup>V600</sup>-mutant cancers in an  
interactive, case-based panel discussion**

Visit our medical booth to vote on the case studies you'd like to be discussed!

Chair



**Josep Tabernero**  
Spain

Faculty



**Reinhard Dummer**  
Switzerland



**Axel Hauschild**  
Germany



**Gregory Riely**  
USA



**Chiara Cremolini**  
Italy

Time	Presentation title	Faculty
18:30–18:35	Welcome and introductions	Josep Tabernero
18:35–18:45	Targeting oncogenic <i>BRAF</i>	Reinhard Dummer
18:45–18:55	<i>BRAF</i> as a breakthrough in the treatment of <i>BRAF</i> <sup>V600</sup> -mutant metastatic melanoma	Axel Hauschild
18:55–19:10	Same strategy, different challenge: Managing <i>BRAF</i> <sup>V600</sup> disease in advanced NSCLC	Gregory Riely
19:10–19:25	Different strategy, same target: Managing <i>BRAF</i> <sup>V600</sup> -mutant metastatic colorectal cancer	Chiara Cremolini
19:25–19:55	Interactive, case-based panel discussion: Optimal care of patients receiving treatment with <i>BRAF</i> -targeted agents	All
19:55–20:00	What's next for this target?	Josep Tabernero



Dear Colleagues,

It is my pleasure to invite you to attend our satellite symposium entitled '**Precision oncology for *BRAF*-mutant cancers**' sponsored by Pierre Fabre Laboratories, which will take place on **Monday, 16 September from 18.30–20.00**, at ESMO 2024.

This interactive symposium will feature an **international panel of experts who will discuss *BRAF*<sup>V600</sup> mutations and their role as oncogenic drivers** in solid tumours. Together, we will explore the role of *BRAF*-targeted therapy in the management of patients with **melanoma, colorectal and lung cancer**, and share with you our key clinical insights in delivering optimal care for these patients. The expert faculty will discuss the rationale for targeting these mutations, the importance of molecular testing and how experiences from the different diseases can be utilised to improve patient care and clinical management of these diseases.

During the symposium, you will have an opportunity to **interact directly with, and pose questions to, our expert panellists**. An engaging and delegate-driven case study discussion will allow you to explore the most relevant aspects of oncogenic *BRAF* mutations to your clinic.

We look forward to welcoming you to our symposium, on what promises to be a highly interesting and educational experience!

Kind regards,



Professor Josep Tabernero

Chair

